Adaptive Biotechnologies Stock

adaptivebiotech.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $561.37MM

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Register for Details

For more details on financing and valuation for Adaptive Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Adaptive Biotechnologies.

Register Today

Team

Management Team

JULIE RUBINSTEIN
President
SEAN NOLAN
Chief Technical Officer
CHAD ROBINS
Chief Executive Officer, Co-founder
LANCE BALDO
Chief Medical Officer
HARLAN ROBINS, PHD
Chief Scientific Officer, Co-founder
CHAD COHEN
Chief Financial Officer

Board Members

PETER NEUPERT
Operating Partner at Health Evolution Partners
MIKE PELLINI, MD
MICHELLE GRIFFIN
Adaptive Biotechnologies
ANDRIS ZOLTNERS
Self
KEVIN CONROY
DAVID GOEL
Matrix Capital Management
CHAD ROBINS
Adaptive Biotechnologies
ERIC DOBMEIER
Adaptive Biotechnologies
ROBERT HERSHBERG, MD, PhD
Celgene

Other companies like Adaptive Biotechnologies in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Adaptive Biotechnologies Revenues Rise 26 Percent in Q4, 57 Percent in 2021
Fourth quarter sequencing revenue increased 81 percent to $23.1 million year over year, while development revenue dropped 15 percent to $14.9 million.
People in the News: New Appointments at BD, Adaptive Biotechnologies, ChromaCode, More
Adaptive Biotechnologies Q1 Revenues up 84 Percent, Beat Analyst Estimates
Updated on: Sep 29, 2023